A new study reveals that one of the most commonly used asthma medicines -- long-acting beta-agonists -- may not be associated with adverse events in people based on their genotype, as previous studies had shown. The study analyzed the effects of long-acting beta-agonist therapy, used in combination with inhaled corticosteroids, in asthmatics who have a specific beta-2 adrenergic receptor genotype. Ten percent of the U.S. population suffers from asthma. Each year, approximately 4,000 people die with asthma as the underlying cause.
More...
Linear Mode
